Bristol-Myers Squibb Stock Price, News & Analysis (NYSE:BMY)

$67.95 +2.01 (+3.05 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$67.95
Today's Range$66.17 - $68.03
52-Week Range$51.56 - $70.05
Volume5.24 million shs
Average Volume9.47 million shs
Market Capitalization$111.21 billion
P/E Ratio28.79
Dividend Yield2.35%
Beta1.08

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:BMY
CUSIP11012210
Phone+1-212-5464000

Debt

Debt-to-Equity Ratio0.59%
Current Ratio1.55%
Quick Ratio1.43%

Price-To-Earnings

Trailing P/E Ratio28.7923728813559
Forward P/E Ratio21.17
P/E Growth2.07

Sales & Book Value

Annual Sales$20.78 billion
Price / Sales5.34
Cash Flow$3.59 per share
Price / Cash18.91
Book Value$7.26 per share
Price / Book9.36

Profitability

Trailing EPS$2.36
Net Income$1.01 billion
Net Margins4.85%
Return on Equity35.43%
Return on Assets14.85%

Miscellaneous

Employees23,700
Outstanding Shares1,632,580,000

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 7th. Investors of record on Friday, January 5th will be paid a dividend of $0.40 per share on Thursday, February 1st. This represents a $1.60 dividend on an annualized basis and a yield of 2.35%. The ex-dividend date is Thursday, January 4th. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.39. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) released its quarterly earnings results on Monday, February, 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The biopharmaceutical company earned $5.45 billion during the quarter, compared to analysts' expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. Bristol-Myers Squibb's quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 earnings per share. View Bristol-Myers Squibb's Earnings History.

When will Bristol-Myers Squibb make its next earnings announcement?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY18 earnings guidance on Monday, February, 5th. The company provided EPS guidance of $3.15-3.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.23.

Where is Bristol-Myers Squibb's stock going? Where will Bristol-Myers Squibb's stock price be in 2018?

15 brokers have issued 12 month price targets for Bristol-Myers Squibb's stock. Their forecasts range from $51.00 to $78.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $66.00 in the next year. View Analyst Ratings for Bristol-Myers Squibb.

What are Wall Street analysts saying about Bristol-Myers Squibb stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb stock:

  • 1. According to Zacks Investment Research, "Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up.  Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last three months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/29/2018)
  • 2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)

Who are some of Bristol-Myers Squibb's key competitors?

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:

  • Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer (Age 53)
  • Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations (Age 58)
  • Ann Powell Judge, Chief Human Resource Officer, Senior Vice President (Age 52)
  • Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer (Age 57)
  • Sandra Leung, Executive Vice President, General Counsel (Age 57)
  • Murdo Gordon, Executive Vice President, Chief Commercial Officer (Age 51)
  • Paul von Autenried, Senior Vice President, Chief Information Officer (Age 56)
  • Joseph C. Caldarella, Senior Vice President, Corporate Controller (Age 62)
  • Karen Santiago, Senior Vice President, Controller (Age 47)
  • John E. Elicker, Senior Vice President - Corporate Affairs and Investor Relations (Age 58)

Who owns Bristol-Myers Squibb stock?

Bristol-Myers Squibb's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), Bank of New York Mellon Corp (1.14%), Geode Capital Management LLC (1.14%), Renaissance Technologies LLC (0.87%), TIAA CREF Investment Management LLC (0.67%) and Orbis Allan Gray Ltd (0.42%). Company insiders that own Bristol-Myers Squibb stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Who sold Bristol-Myers Squibb stock? Who is selling Bristol-Myers Squibb stock?

Bristol-Myers Squibb's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Two Sigma Advisers LP, Credit Agricole S A, Two Sigma Investments LP, Metropolitan Life Insurance Co. NY, Retirement Systems of Alabama, Clearbridge LLC and OppenheimerFunds Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.

Who bought Bristol-Myers Squibb stock? Who is buying Bristol-Myers Squibb stock?

Bristol-Myers Squibb's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, TIAA CREF Investment Management LLC, Orbis Allan Gray Ltd, Amundi Pioneer Asset Management Inc., Arrowstreet Capital Limited Partnership, Bank of Montreal Can and Teachers Advisors LLC. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy Bristol-Myers Squibb stock?

Shares of Bristol-Myers Squibb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of Bristol-Myers Squibb stock can currently be purchased for approximately $67.95.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $111.21 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $2.36 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK, NY 10154, United States. The biopharmaceutical company can be reached via phone at +1-212-5464000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  711 (Vote Outperform)
Underperform Votes:  666 (Vote Underperform)
Total Votes:  1,377
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bristol-Myers Squibb (NYSE:BMY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.402.442.442.50
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.00$65.00$63.92$61.71
Price Target Upside: 4.32% downside2.72% upside6.65% upside6.64% upside

Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History

Price Target History for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018CitigroupSet Price TargetBuy$78.00LowView Rating Details
2/15/2018Morgan StanleyUpgradeEqual Weight -> Overweight$51.56 -> $78.00HighView Rating Details
2/14/2018BMO Capital MarketsSet Price TargetSell$51.00LowView Rating Details
2/6/2018Leerink SwannBoost Price TargetOutperform -> Positive$71.00 -> $76.00MediumView Rating Details
1/22/2018Credit Suisse GroupSet Price TargetHold$62.00LowView Rating Details
10/30/2017SunTrust BanksUpgradeHold -> BuyN/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$60.00N/AView Rating Details
10/16/2017Jefferies GroupDowngradeBuy -> Hold$72.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$58.00 -> $65.00N/AView Rating Details
9/19/2017CowenReiterated RatingHold$65.00LowView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy -> Neutral$65.00LowView Rating Details
9/7/2017Goldman Sachs GroupReiterated RatingBuy$62.00 -> $65.00LowView Rating Details
7/17/2017Deutsche BankSet Price TargetHold$54.00 -> $55.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/21/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart

Earnings by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.83N/AView Earnings Details
2/5/2018Q4 2017$0.67$0.68$5.35 billion$5.45 billionViewListenView Earnings Details
10/26/2017Q3 2017$0.77$0.75$5.20 billion$5.25 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.09 billion$5.14 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates

2018 EPS Consensus Estimate: $3.16
2019 EPS Consensus Estimate: $3.81
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.74$0.84$0.79
Q2 20182$0.76$0.81$0.79
Q3 20182$0.77$0.78$0.78
Q4 20182$0.78$0.84$0.81
Q1 20191$0.91$0.91$0.91
Q2 20191$0.95$0.95$0.95
Q3 20191$0.97$0.97$0.97
Q4 20191$0.98$0.98$0.98
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Bristol-Myers Squibb (NYSE:BMY) Dividend Information

Most Recent Dividend:2/1/2018
Annual Dividend:$1.60
Dividend Yield:2.35%
Dividend Growth:2.70% (3 Year Average)
Payout Ratio:67.80% (Trailing 12 Months of Earnings)
49.84% (Based on This Year's Estimates)
40.61% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/7/2017quarterly$0.402.56%1/4/20181/5/20182/1/2018
9/13/2017quarterly$0.392.49%10/5/201710/6/201711/1/2017
6/13/2017quarterly$0.392.86%7/5/20177/7/20178/1/2017
3/2/2017quarterly$0.392.72%4/5/20174/7/20175/1/2017
12/8/2016quarterly$0.392.73%1/4/20171/6/20172/1/2017
8/3/2016quarterly$0.382.02%10/5/201610/7/201611/1/2016
6/7/2016quarterly$0.382.07%6/29/20167/1/20168/1/2016
3/3/2016quarterly$0.382.35%3/30/20164/1/20165/2/2016
12/8/2015quarterly$0.382.22%12/30/20151/4/20162/1/2016
9/17/2015quarterly$0.372.3%9/30/201510/2/201511/2/2015
6/16/2015quarterly$0.372.23%7/1/20157/6/20158/3/2015
3/2/2015quarterly$0.372.39%4/1/20154/6/20155/1/2015
12/9/2014quarterly$0.372.5%12/30/20141/2/20152/2/2015
9/16/2014quarterly$0.362.83%10/1/201410/3/201411/3/2014
6/17/2014quarterly$0.363%7/1/20147/3/20148/1/2014
3/3/2014quarterly$0.362.55%4/2/20144/4/20145/1/2014
12/19/2013quarterly$0.362.7%12/31/20131/3/20142/3/2014
9/17/2013quarterly$0.352.95%10/2/201310/4/201311/1/2013
6/19/2013quarterly$0.353.14%7/2/20137/5/20138/1/2013
3/7/2013quarterly$0.353.74%4/3/20134/5/20135/1/2013
12/4/2012quarterly$0.351/4/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.82%
Insider Trades by Quarter for Bristol-Myers Squibb (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Theodore R Samuels IIDirectorBuy4,000$62.30$249,200.0022,000View SEC Filing  
12/12/2017Thomas J Jr. LynchEVPSell5,300$63.24$335,172.009,251View SEC Filing  
12/4/2017Sandra LeungEVPSell156,582$63.37$9,922,601.34584,373View SEC Filing  
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.0046,297View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.0018,000View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00952,571View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00986,112View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00986,112View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.0021,483View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.8455,637View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10488,063View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.0012,000View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00334,499View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00364,999View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00380,099View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00403,094View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.8055,011View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79184,694View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.9355,238View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16444,507View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00425,194View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14132,263View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94128,463View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60536,794View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.1021,971View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00453,094View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00453,094View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00381,254View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.002,500View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.6846,322View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.2076,738View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64309,547View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00392,854View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00310,424View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00310,424View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00332,852View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00456,052View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00524,252View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00546,874View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.4068,965View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00630,783View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.198,861View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00273,393View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.1214,696View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.7249,753View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.4832,740View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00207,237View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.0577,303View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20195,855View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50500,487View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.9059,355View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00373,393View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:
DateHeadline
Beese Fulmer Investment Management Inc. Has $3.76 Million Position in Bristol-Myers Squibb Co (BMY)Beese Fulmer Investment Management Inc. Has $3.76 Million Position in Bristol-Myers Squibb Co (BMY)
www.americanbankingnews.com - February 24 at 4:50 AM
Commerzbank Aktiengesellschaft FI Sells 8,501 Shares of Bristol-Myers Squibb Co (BMY)Commerzbank Aktiengesellschaft FI Sells 8,501 Shares of Bristol-Myers Squibb Co (BMY)
www.americanbankingnews.com - February 24 at 4:50 AM
Moloney Securities Asset Management LLC Sells 1,809 Shares of Bristol-Myers Squibb Co (BMY)Moloney Securities Asset Management LLC Sells 1,809 Shares of Bristol-Myers Squibb Co (BMY)
www.americanbankingnews.com - February 24 at 4:50 AM
Bristol-Myers Squibb Co (BMY) Holdings Reduced by Foundry Partners LLCBristol-Myers Squibb Co (BMY) Holdings Reduced by Foundry Partners LLC
www.americanbankingnews.com - February 24 at 4:50 AM
Bristol-Myers Squibb Co (BMY) Stake Lifted by Robeco Institutional Asset Management B.V.Bristol-Myers Squibb Co (BMY) Stake Lifted by Robeco Institutional Asset Management B.V.
www.americanbankingnews.com - February 24 at 4:50 AM
Bristol-Myers Squibb Co (BMY) Holdings Lifted by Lourd Capital LLCBristol-Myers Squibb Co (BMY) Holdings Lifted by Lourd Capital LLC
www.americanbankingnews.com - February 24 at 4:50 AM
Sumitomo Mitsui Asset Management Company LTD Sells 7,862 Shares of Bristol-Myers Squibb Co (BMY)Sumitomo Mitsui Asset Management Company LTD Sells 7,862 Shares of Bristol-Myers Squibb Co (BMY)
www.americanbankingnews.com - February 24 at 4:42 AM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bristol-Myers Squibb Company – BMYEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bristol-Myers Squibb Company – BMY
finance.yahoo.com - February 23 at 5:12 PM
Zacks: Analysts Expect Bristol-Myers Squibb Co (BMY) to Announce $0.87 EPSZacks: Analysts Expect Bristol-Myers Squibb Co (BMY) to Announce $0.87 EPS
www.americanbankingnews.com - February 23 at 3:12 AM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Bristol-Myers Squibb Company (BMY)The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Bristol-Myers Squibb Company (BMY)
finance.yahoo.com - February 22 at 5:16 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bristol-Myers Squibb Company to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bristol-Myers Squibb Company to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - February 22 at 5:16 PM
Form 3 BRISTOL MYERS SQUIBB CO For: Feb 15 Filed by: Santiago Karen MurphyForm 3 BRISTOL MYERS SQUIBB CO For: Feb 15 Filed by: Santiago Karen Murphy
www.streetinsider.com - February 22 at 8:37 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018 SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018 
finance.yahoo.com - February 21 at 5:16 PM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Bristol-Myers Squibb CompanyThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Bristol-Myers Squibb Company
finance.yahoo.com - February 21 at 5:16 PM
Basileas CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of DirectorsBasilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
feeds.benzinga.com - February 21 at 3:18 AM
What Are Bristol Myers Squibbs Key Sources of Revenue?What Are Bristol Myers Squibb's Key Sources of Revenue?
www.nasdaq.com - February 20 at 5:09 PM
Bristol-Myers Squibb: Next Stop, Record LevelsBristol-Myers Squibb: Next Stop, Record Levels
seekingalpha.com - February 20 at 5:09 PM
Bristol-Myers Squibb (BMY) and Celgene (CELG) Critical ContrastBristol-Myers Squibb (BMY) and Celgene (CELG) Critical Contrast
www.americanbankingnews.com - February 20 at 3:10 AM
Citigroup Reiterates $78.00 Price Target for Bristol-Myers Squibb (BMY)Citigroup Reiterates $78.00 Price Target for Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - February 16 at 9:18 PM
3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb
finance.yahoo.com - February 16 at 5:13 PM
Bristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% HigherBristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% Higher
finance.yahoo.com - February 16 at 5:13 PM
With A -77.41% Earnings Drop Lately, Did Bristol-Myers Squibb Company (NYSE:BMY) Underperform Its Industry?With A -77.41% Earnings Drop Lately, Did Bristol-Myers Squibb Company (NYSE:BMY) Underperform Its Industry?
finance.yahoo.com - February 16 at 5:13 PM
BMY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb CompanyBMY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company
finance.yahoo.com - February 16 at 5:13 PM
Q3 2018 EPS Estimates for Bristol-Myers Squibb Co Decreased by William Blair (BMY)Q3 2018 EPS Estimates for Bristol-Myers Squibb Co Decreased by William Blair (BMY)
www.americanbankingnews.com - February 16 at 11:06 AM
Bristol-Myers Squibb (BMY) Raised to "Overweight" at Morgan StanleyBristol-Myers Squibb (BMY) Raised to "Overweight" at Morgan Stanley
www.americanbankingnews.com - February 15 at 9:40 PM
Morgan Stanley Upgrades Bristol-Myers Squibb Co. (BMY) to OverweightMorgan Stanley Upgrades Bristol-Myers Squibb Co. (BMY) to Overweight
www.streetinsider.com - February 15 at 5:16 PM
Bristol-Myerss stock surges toward 18-month high after Morgan Stanley turns bullishBristol-Myers's stock surges toward 18-month high after Morgan Stanley turns bullish
www.marketwatch.com - February 15 at 5:16 PM
Rock and Roll: Bristol-Myers Squibb Is Breaking OutRock and Roll: Bristol-Myers Squibb Is Breaking Out
finance.yahoo.com - February 15 at 5:16 PM
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To OverweightMorgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
finance.yahoo.com - February 15 at 5:16 PM
Stocks Try To Extend Win Streak As Dow Tests This Key LevelStocks Try To Extend Win Streak As Dow Tests This Key Level
finance.yahoo.com - February 15 at 5:16 PM
Bristol-Myers Is Back and Could Soar Another 14%Bristol-Myers 'Is Back' and Could Soar Another 14%
finance.yahoo.com - February 15 at 5:16 PM
These Were the 3 Hottest Stories on Wall Street ThursdayThese Were the 3 Hottest Stories on Wall Street Thursday
finance.yahoo.com - February 15 at 5:16 PM
Q1 2019 EPS Estimates for Bristol-Myers Squibb Co Cut by Analyst (BMY)Q1 2019 EPS Estimates for Bristol-Myers Squibb Co Cut by Analyst (BMY)
www.americanbankingnews.com - February 15 at 2:32 PM
Pay Your Money And Hold Your Breath - Seeking AlphaPay Your Money And Hold Your Breath - Seeking Alpha
seekingalpha.com - February 15 at 7:08 AM
Pharma giant Bristol-Myers Squibb is spending $1.85 billion on a cancer drugPharma giant Bristol-Myers Squibb is spending $1.85 billion on a cancer drug
www.businessinsider.com - February 14 at 3:30 PM
Bristol-Myers Squibb’s Valuation after Its 4Q17 EarningsBristol-Myers Squibb’s Valuation after Its 4Q17 Earnings
finance.yahoo.com - February 14 at 3:30 PM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb CompanyIMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb Company
finance.yahoo.com - February 14 at 3:30 PM
BMO Capital Markets Analysts Give Bristol-Myers Squibb (BMY) a $51.00 Price TargetBMO Capital Markets Analysts Give Bristol-Myers Squibb (BMY) a $51.00 Price Target
www.americanbankingnews.com - February 14 at 1:38 PM
Bristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Partner on NKTR-214 in $1.85B+ Deal - StreetInsider.comBristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Partner on NKTR-214 in $1.85B+ Deal - StreetInsider.com
www.streetinsider.com - February 14 at 7:11 AM
Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214
finance.yahoo.com - February 14 at 7:11 AM
Bristol-Myers To Pay Largest Licensing Fee In Biotech History For Nektar Cancer DrugBristol-Myers To Pay Largest Licensing Fee In Biotech History For Nektar Cancer Drug
finance.yahoo.com - February 14 at 7:11 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY
finance.yahoo.com - February 13 at 3:27 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb CompanyINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company
finance.yahoo.com - February 13 at 3:27 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb ... - PR Newswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb ... - PR Newswire (press release)
www.prnewswire.com - February 13 at 7:10 AM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company (NYSE: BMY) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company (NYSE: BMY) To Contact Brower Piven Before The Lead Plaintiff Deadline
feeds.benzinga.com - February 12 at 9:27 PM
Bristol-Myers Squibb Co (BMY) Forecasted to Earn FY2018 Earnings of $3.30 Per ShareBristol-Myers Squibb Co (BMY) Forecasted to Earn FY2018 Earnings of $3.30 Per Share
www.americanbankingnews.com - February 12 at 6:54 AM
Bristol-Myers Squibb (BMY) Downgraded by Vetr to "Sell"Bristol-Myers Squibb (BMY) Downgraded by Vetr to "Sell"
www.americanbankingnews.com - February 11 at 7:30 PM
Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Bristol-Myers Squibb Company Investors ... - Business Wire (press release)Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Bristol-Myers Squibb Company Investors ... - Business Wire (press release)
www.businesswire.com - February 10 at 7:07 AM
Bristol-Myers Squibb Co Expected to Post FY2021 Earnings of $5.45 Per Share (BMY)Bristol-Myers Squibb Co Expected to Post FY2021 Earnings of $5.45 Per Share (BMY)
www.americanbankingnews.com - February 9 at 6:14 PM
Bristol-Myers Squibb to Take Part in Leerink 7th Annual Global Healthcare ConferenceBristol-Myers Squibb to Take Part in Leerink 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:27 PM

SEC Filings

Bristol-Myers Squibb (NYSE:BMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bristol-Myers Squibb (NYSE BMY) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.